Tempus AI (NASDAQ:TEM) Director Sells 2,673 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 2,673 shares of Tempus AI stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the sale, the director directly owned 25,942 shares of the company’s stock, valued at approximately $1,426,810. This trade represents a 9.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM opened at $58.31 on Tuesday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $10.47 billion, a P/E ratio of -33.90 and a beta of 3.64. The stock has a 50-day moving average price of $50.14 and a 200-day moving average price of $54.80. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.24) EPS. Equities analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares during the period. Rhumbline Advisers bought a new stake in Tempus AI in the first quarter valued at approximately $116,000. Prudential Financial Inc. purchased a new stake in shares of Tempus AI during the second quarter valued at approximately $276,000. Russell Investments Group Ltd. boosted its stake in shares of Tempus AI by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after purchasing an additional 1,146 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Tempus AI by 2,926.6% in the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on TEM shares. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Guggenheim cut their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a report on Monday, June 1st. BTIG Research reiterated a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Finally, Jefferies Financial Group began coverage on shares of Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.54.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.